Treatment with Tildrakizumab Effective for Scalp Psoriasis in Phase 3b StudyJanuary 14, 2025PsoriasisPsoriatic Arthritis
Cardiac Risks of Newer Psoriasis Biologics vs. TNF Inhibitors ComparedJanuary 7, 2025PsoriasisPsoriatic Arthritis
Combined Clinics, Personalized Medicine for Psoriatic Disease Face BarriersJanuary 2, 2025Psoriatic ArthritisPsoriasis
FDA Approves Ustekinumab Biosimilar Steqeyma, the Seventh of Its KindDecember 19, 2024Psoriatic ArthritisPsoriasis
Adalimumab for Psoriasis: Study Compares Biosimilars Vs. OriginatorDecember 2, 2024PsoriasisPsoriatic Arthritis
Updated Guidance for Psoriatic Arthritis Ultrasound Comes at Time of Growing Use, New TechnologyNovember 18, 2024Psoriatic ArthritisPsoriasis
Study Supports Efficacy of Home-Based Phototherapy for PsoriasisOctober 3, 2024PsoriasisPsoriatic Arthritis
Bimekizumab Gains FDA Approval for Psoriatic Arthritis, Axial SpondyloarthritisSeptember 24, 2024Psoriatic ArthritisPsoriasis
Topical Tapinarof and Roflumilast for Psoriasis: Where Do they Fit In?September 10, 2024PsoriasisPsoriatic Arthritis
Ustekinumab’s ‘Egregious’ Medicare Part B and D Pricing Differences Led to Federal InterventionAugust 30, 2024Business of MedicinePsoriatic ArthritisPsoriasis
New Associations Identified Between IBD and Extraintestinal ManifestationsAugust 29, 2024Psoriatic Arthritis
Patients With Immune-Mediated Inflammatory Diseases, Type 2 Diabetes Reap GLP-1 Receptor Agonist Benefits, TooAugust 23, 2024Psoriatic ArthritisPsoriasisAutoimmune Diseases
